SEC Filing Analysis: CalciMedica, Inc. (CALC)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director of CalciMedica, Inc. was granted 937 stock options with an exercise price of $3.26 as a routine component of compensation.
• Market Impact: The transaction is expected to have a neutral market impact due to its nature as a standard compensation grant with zero immediate market value.

Company Information

Field	Value
Company	CalciMedica, Inc.
Ticker Symbol	CALC
CIK	0001534133
Industry	PHARMACEUTICAL PREPARATIONS [2834]

Insider Information

Field	Value
Name	Glicklich Alan
CIK	0001823197
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-13
Transaction Code	A (Grant, award, or other acquisition)
Security Type	Director Stock Option (Right to Buy)
Shares Involved	937
Price Per Share	$0.00
Total Value	$0.00
Shares Owned After	937 (options)
Ownership Type	Direct

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is not an open-market purchase or sale reflecting insider sentiment. It is a pre-planned grant of stock options as part of a director's compensation package. Such events are common and do not typically influence stock price.

Volume & Sentiment

• Expected Volume Impact: Negligible. As this is not a market transaction, it will not directly impact trading volume.
• Sentiment Indicator: Neutral. The grant does not provide a bullish or bearish signal regarding the insider's view of the company's future prospects.

Investment Insights

Positive Market Indicators

• Aligning director interests with shareholders through equity-based compensation is a standard corporate governance practice.

Risk Factors

• The transaction itself presents no new risk factors. It is a routine corporate action.

Key Takeaways

1. Routine Compensation: The transaction is a grant of stock options, a common form of non-cash compensation for directors.
2. No Market Value: The transaction was executed at $0 per share, resulting in a total value of $0. The value will only be realized if the stock price exceeds the exercise price of $3.26 and the director chooses to exercise the options after they vest.
3. Vesting Schedule: The options have a vesting schedule, as noted in the filing's footnote: "Beginning October 1, 2025, 1/3rd of the shares subject to the option shall vest in equal monthly installments." This means the director does not have immediate access to the underlying shares.

Contextual Analysis

Timing Significance

There is no particular timing significance to this grant. It is a routine part of director compensation and not timed in relation to any specific market event.

Transaction Context

This is a derivative transaction coded 'A' for Award. The insider acquired options, not common stock, directly from the company at no cost. The options expire on October 12, 2035.

Company Context

CalciMedica, Inc. operates in the pharmaceutical preparations industry. Investors should view this filing in the context of the company's overall compensation strategy for its board members rather than as a specific trading signal.

Risk Assessment

Risk Level: Low

Risk Factors

• This filing does not introduce any new risks to the investment thesis for CALC.

Market Considerations

• The market generally disregards routine option grants to insiders as they are not indicative of new information or a change in an insider's outlook.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-14 | Data source: SEC EDGAR